{
  "docId": "019de076-b515-770b-a5e9-c449fc01e3f7",
  "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4",
  "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
  "authorId": "neurobo-pharmaceuticals",
  "authorName": "NeuroBo Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 25,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses preclinical data to demonstrate efficacy superiority over a market-leading GLP-1 agonist.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/18",
  "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7",
  "deckJsonHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7.json",
  "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Cumulative Food intake in HF-DIO Obese Mice",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b111068-cb34-4b11-a73c-bd33b4bce6fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.32,
        "y": 0.3
      },
      "kind": "chart",
      "text": "BWL in HF-DIO Obese Mice DA-1726 vs Semaglutide",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e6acf44-3abf-49bf-95fa-9107bedcb7f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.65,
        "y": 0.3
      },
      "kind": "chart",
      "text": "BWL in HF-FATZO T2DM/Obese Mice DA-1726 vs Semaglutide",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da1529ca-86cd-4f78-8ee4-ea9de5c7baa7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "*Statistically significant compared to control. Notes: GLP1R/GCGR (Glucagon-Like Peptide 1 Receptor/ Glucagon Receptor); HF-DIO (High Fat-Diet Induced Obesity); GLP-1 (Glucagon-Like Peptide 1). 1-3: Study references.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c78efead-af7e-4087-9f6f-c2fbe7b71e69",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.05,
        "y": 0.7
      },
      "kind": "paragraph",
      "text": "Weight loss observed from DA-1726 is attributed to reduced food intake via GLP1R and increased energy expenditure via the GCGR",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90b79af4-001d-4aa8-8878-b32e17044ce2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "title",
      "text": "DA-1726 outperformed Semaglutide (WEGOVY™), a GLP-1 agonist, in mouse models of obesity*",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0981f0a-1e7c-48e8-8161-ed82456003b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "DA-1726: Therapeutic Potential in Obesity(1-3) — Semaglutide Comparison",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f929a42-9e99-4064-8b16-1c1989c9ea15",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "b5862f9a-feea-4e65-84eb-f36160b4e666",
      "evidence": "Direct comparison of drug efficacy against market standard",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 15,
      "beatId": "3fbd2aa2-3e57-4d4f-b65f-ea90e59c9f1a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "Slides 15-20 discuss the therapeutic potential of DA-1726 in obesity",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 24,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e",
      "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)",
      "position": 1,
      "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}